Haleon plc (HLN)

10.51 +0.13 (+1.25%) 收市：04:00PM EDT

Haleon plc

The Heights
Building 5, First Floor
Weybridge KT13 0NY
United Kingdom
44 1932 822000
https://www.haleon.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 25,408

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Brian James McNamara	CEO & Executive Director	4.49M	無	1966
Mr. Tobias Hannes Hestler	CFO & Executive Director	2.49M	無	1972

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

公司管治

截至 2024年9月1日 止，Haleon plc 的 ISS 管治質素評分為 2。 Pillar 分數正在審核中：6；董事會：3；股東權利：1；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。